IL‑22 expression is increased variedly in the initial phase, onset and chronic phase of a pristane‑induced arthritis rat model

Hou,Weikun; Wang,Bo; Zhou,Yan; Xu,Ke; Meng,Liesu; Zhu,Wenhua; Jiang,Congshan; Xu,Peng; Lu,Shemin

doi:10.3892/mmr.2017.6739

IL‑22 expression is increased variedly in the initial phase, onset and chronic phase of a pristane‑induced arthritis rat model

Authors:
- Weikun Hou
- Bo Wang
- Yan Zhou
- Ke Xu
- Liesu Meng
- Wenhua Zhu
- Congshan Jiang
- Peng Xu
- Shemin Lu
View Affiliations

Affiliations: Osteonecrosis and Joint Reconstruction Ward, Department of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710054, P.R. China, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, P.R. China
Published online on: June 9, 2017 https://doi.org/10.3892/mmr.2017.6739
Pages: 1109-1116
Copyright: © Hou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the expression pattern of T helper (Th) 17 and Th22 cell-related factors in a pristane‑induced arthritis (PIA) rat model. PIA rats were divided into the initial phase group [day (D) 6 post‑pristane injection], the onset of clinical arthritis group (D12), the acute arthritis group (D26) and the chronic arthritis group (D70). Rats injected with saline alone were used as the control group. The mRNA expression levels of interleukin (IL)‑17A, IL‑17F, interferon (IFN)‑γ, IL‑22, IL‑22 receptor (R) 1, IL‑22 binding protein (BP) and RAR‑related orphan receptor α were examined in the spleen and/or synovium of the various phases of PIA rats by reverse transcription‑quantitative polymerase chain reaction analysis. The results demonstrated that, in the spleen, IL‑22 exhibited an increasing trend in both the initial phase and the onset of disease, while the ratio of IL‑22R1/IL‑22BP increased in both phases, compared with the control group. During the acute arthritis phase, IL‑17F and IFN‑γ were significantly increased and IL‑17A exhibited an increasing tendency in the synovium, compared with the control group. In the chronic phase, IL‑22, IL‑22R1 and IFN‑γ were increased in the spleen, while IL‑22 exhibited an increasing trend in the synovium. In addition, immunohistochemistry analysis was used to evaluate the expression of IL‑17A, IL‑21, IL‑22 and IL‑22R1 in the ankle joints of D26 PIA rats. IL‑17A was mainly expressed in infiltrated inflammatory cells in the synovium. IL‑21 and IL‑22 were both expressed in the inflammatory cells and in the articular chondrocyte of the proliferative zone. IL‑22R1 was expressed in proliferating synovial cells. In conclusion, Th17 and Th22‑related factor expression varied in different disease progression phases and in different tissues in PIA rats. IL‑22 expression exhibited an increasing trend in the initial phase and the onset phase of arthritis and increased significantly with progression to chronic arthritis in the PIA rat model. It is thought that IL‑22 may serve an important role in the pathological process of PIA, particularly in the chronic fluctuation phase. Therefore, it may be a candidate molecule for the treatment of rheumatoid arthritis.

View Figures

View References

1	Huber LC, Distler O, Tarner I, Gay RE, Gay S and Pap T: Synovial fibroblasts: Key players in rheumatoid arthritis. Rheumatology (Oxford). 45:669–675. 2006. View Article : Google Scholar : PubMed/NCBI
2	O'Mahony R, Richards A, Deighton C and Scott D: Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A systematic review and meta-analysis. Ann Rheum Dis. 69:1823–1826. 2010. View Article : Google Scholar : PubMed/NCBI
3	Hou W, Meng L, Tian L, Zhu W, Jiang C and Lu S: A systematic comparison between collagen-induced arthritis and pristane-induced arthritis in Dark Agouti rats. Clin Exp Rheumatol. 28:532–538. 2010.PubMed/NCBI
4	Vingsbo C, Sahlstrand P, Brun JG, Jonsson R, Saxne T and Holmdahl R: Pristane-induced arthritis in rats: A new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility. complex genes. 149:1675–1683. 1996.
5	Lu S, Nordquist N, Holmberg J, Olofsson P, Pettersson U and Holmdahl R: Both common and unique susceptibility genes in different rat strains with pristane-induced arthritis. Eur J Hum Genet. 10:475–483. 2002. View Article : Google Scholar : PubMed/NCBI
6	Holmberg J, Tuncel J, Yamada H, Lu S, Olofsson P and Holmdahl R: Pristane, a non-antigenic adjuvant, induces MHC class II-restricted, arthritogenic T cells in the rat. J Immunol. 176:1172–1179. 2006. View Article : Google Scholar : PubMed/NCBI
7	Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM and Weaver CT: Interleukin 17-producing CD4⁺ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 6:1123–1132. 2005. View Article : Google Scholar : PubMed/NCBI
8	Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA, Kamenecka TM, Roush WR, Vidović D, et al: Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 472:491–494. 2011. View Article : Google Scholar : PubMed/NCBI
9	Duhen T, Geiger R, Jarrossay D, Lanzavecchia A and Sallusto F: Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 10:857–863. 2009. View Article : Google Scholar : PubMed/NCBI
10	Wolk K, Witte E, Witte K, Warszawska K and Sabat R: Biology of interleukin-22. Semin Immunopathol. 32:17–31. 2010. View Article : Google Scholar : PubMed/NCBI
11	Dumoutier L, Lejeune D, Colau D and Renauld JC: Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol. 166:7090–7095. 2001. View Article : Google Scholar : PubMed/NCBI
12	Sarkar S, Justa S, Brucks M, Endres J, Fox DA, Zhou X, Alnaimat F, Whitaker B, Wheeler JC, Jones BH and Bommireddy SR: Interleukin (IL)-17A, F and AF in inflammation: A study in collagen-induced arthritis and rheumatoid arthritis. Clin Exp Immunol. 177:652–661. 2014. View Article : Google Scholar : PubMed/NCBI
13	Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H and Maslinski W: High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol. 164:2832–2838. 2000. View Article : Google Scholar : PubMed/NCBI
14	Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K and Nojima Y: Expression of interleukin-22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. Arthritis Rheum. 52:1037–1046. 2005. View Article : Google Scholar : PubMed/NCBI
15	Sarkar S, Zhou X, Justa S and Bommireddy SR: Interleukin-22 reduces the severity of collagen-induced arthritis in association with increased levels of interleukin-10. Arthritis Rheum. 65:960–971. 2013. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Olofsson P and Holmdahl R: Pristane-induced arthritis in the rat. Methods Mol Med. 136:255–268. 2007. View Article : Google Scholar : PubMed/NCBI
18	Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC and Matthys P: Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 60:390–395. 2009. View Article : Google Scholar : PubMed/NCBI
19	Pinto LG, Talbot J, Peres RS, Franca RF, Ferreira SH, Ryffel B, Aves-Filho JC, Figueiredo F, Cunha TM and Cunha FQ: Joint production of IL-22 participates in the initial phase of antigen-induced arthritis through IL-1β production. Arthritis Res Ther. 17:2352015. View Article : Google Scholar : PubMed/NCBI
20	Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, et al: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 183:2593–2603. 1996. View Article : Google Scholar : PubMed/NCBI
21	Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F and Pelletier JP: IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol. 160:3513–3521. 1998.PubMed/NCBI
22	Katz Y, Nadiv O and Beer Y: Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6 and 8 in skin and synovial fibroblasts: A possible role as a ‘fine-tuning cytokine’ in inflammation processes. Arthritis Rheum. 44:2176–2184. 2001. View Article : Google Scholar : PubMed/NCBI
23	Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, et al: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 103:1345–1352. 1999. View Article : Google Scholar : PubMed/NCBI
24	Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F and Pelletier JP: IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol. 160:3513–3521. 1998.PubMed/NCBI
25	Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, et al: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 103:1345–1352. 1999. View Article : Google Scholar : PubMed/NCBI
26	Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F and Miossec P: Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine. 12:1092–1099. 2000. View Article : Google Scholar : PubMed/NCBI
27	Benderdour M, Tardif G, Pelletier JP, Di Battista JA, Reboul P, Ranger P and Martel-Pelletier J: Interleukin 17 (IL-17) induces collagenase-3 production in human osteoarthritic chondrocytes via AP-1 dependent activation: Differential activation of AP-1 members by IL-17 and IL-1beta. J Rheumatol. 29:1262–1272. 2002.PubMed/NCBI
28	Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE and Rowan AD: Interleukin 17 induces cartilage collagen breakdown: Novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis. 61:704–713. 2002. View Article : Google Scholar : PubMed/NCBI
29	Grassi W, de Angelis R, Lamanna G and Cervini C: The clinical features of rheumatoid arthritis. Eur J Radiol. 27 Suppl 1:S18–S24. 1998. View Article : Google Scholar : PubMed/NCBI
30	Marijnissen RJ, Koenders MI, Smeets RL, Stappers MH, Nickerson-Nutter C, Joosten LA, Boots AM and van den Berg WB: Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation. Arthritis Rheum. 63:2939–2948. 2011. View Article : Google Scholar : PubMed/NCBI